OUR NEWS

04/12/2025 LAIGOBIO

Laigo Bio raises €11.5 million in seed financing to advance its SureTAC™ targeted protein degradation candidates in oncology and auto-immunity

We’re proud to announce that Laigo Bio has raised €11.5M in seed funding to accelerate development of our SureTAC™ precision membrane protein degradation platform. This investment will drive our oncology programs toward the clinic and speed the discovery of our immunology candidates targeting autoimmune disease and graft rejection.     PRESS RELEASE Laigo...

Read more

15/10/2024 News

Laigo Bio secures Health~Holland PPP Innovation Subsidy for Advancing Targeted Protein Degradation

Translating SureTACs to the clinic Laigo Bio has been awarded a TKI-MKB (SME) grant to further develop its SureTAC technology in collaboration with UMC Utrecht and Oncode Institute. This funding will support critical steps in optimizing SureTAC molecules, pushing them through the lead optimization phase and bringing them to the development candidate nomination stage. This will...

Read more

03/07/2024 News

Laigo Bio Summer meeting June 2024

The Laigo Bio SureTACs team met in Utrecht at the end of June for two days of SureTACs, science and sunshine!        

Read more

15/01/2023 News

Laigo co-founder Madelon Maurice receives additional Health Holland funding to study E3 ligases for targeted degradation of membrane proteins in cancer in partnership with Laigo Bio B.V.

Read more

26/10/2022 Publication

RNF43 mutations facilitate mucinous colorectal cancer metastasis via formation of a tumour-intrinsic niche BioRxiv preprint 2022

Bugter JM, El Bouazzaoui L, Küçükköse E, Hong Y, Sprangers J, Jordens I, Fenderico N, Montiel Gonzalez D, Van Boxtel R, Suijkerbuijk SJE, Tejpar S, Snippert HJG, Kranenburg O, Maurice MM.

Read more

28/07/2022 News

Laigo co-founder Madelon Maurice receives KWF and Health Holland funding to further study the innovative SureTAC technology, designed in collaboration with ArgoBio and Oncode, to degrade cancer-specific proteins

Prof. Madelon Maurice's group at UMC Utrecht has been awarded 1.2 million for its research into the effect of a new technology they have developed for eliminating cancer proteins. The project is funded by KWF, which stimulates public-private partnerships with government money through the top sector Life Sciences & Health (under the name Health-Holland).  Targeted...

Read more

08/02/2022 News

Oncode Institute and ArgoBio launch Laigo Bio, a targeted protein degradation biotech with programs in oncology and neurological disorders

A collaboration for the creation of a company specialized in the development of a new biological approach for the treatment of cancer and neurological disorders.   Argobio and the Oncode Institute will support the company's development to Series A financing. Utrecht (Netherlands), and Paris (France), February 08th 2022 - ArgoBio and Oncode Institute have...

Read more

26/10/2020 Publication

RNF43 truncations trap CK1 to drive niche‐independent self‐renewal in cancer - The EMBO Journal (2020)

Spit M., Fenderico N., Jordens I., Radaszkiewicz T., Lindeboom R.G., Bugter J.M., Cristobal A., Ootes L., van Osch M., Janssen E., Boonekamp K.E., Hanakova K., Potesil D., Zdrahal Z., Boj S.F., Medema J.P., Bryja V., Koo B., Vermeulen M., & Maurice M.M.  

Read more

26/10/2012 Publication

Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors - Nature (2012). PMID: 22895187

Koo BK, Spit M, Jordens I, Low TY, Stange DE, van de Wetering M, van Es JH, Mohammed S, Heck AJ, Maurice MM, Clevers H.

Read more